Supplementary Figures S1-S12 from Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer

Supplementary Figure S1: Correlation of REGN421 serum concentrations and anti-HT1080 tumor activity Supplementary Figure S2: The potent anti-tumor activity of targeting Dll4 in ovarian xenograft models is dependent on blocking stromal Dll4 Supplementary Figure S3: Dll4 antibody REGN1035 treatment induces abnormal tumor vessels in ovarian cancer xenograft models Supplementary Figure S4: Dll4 expression in ovarian cancer xenograft models is restricted to the tumor vasculature Supplementary Figure S5: Notch receptor expression in ovarian cancer xenograft models Supplementary Figure S6: Notch signaling in TOV-112D cells is mediated predominantly by Notch1 Supplementary Figure S7: Combined blockade of Dll4 and VEGF reverses liver vascular changes induced by Dll4 blockade alone Supplementary Figure S8: Dll4 is expressed in the endothelium of adult heart and liver Supplementary Figure S9: Notch1 signaling activity in heart and liver is dependent on Dll4 Supplementary Figure S10: Pericyte coverage in ovarian xenograft tumors is unaltered in response to anti-Dll4 antibody treatment Supplementary Figure S11: Direct contact between endothelial and tumor cells in TOV-112D tumors Supplementary Figure S12: Direct contact between endothelial and tumor cells in A2780 tumors